VASCULITIS SYNDROMES: Edited by Hasan Yazici and Yusuf YaziciA treat-to-target approach is needed for Behçet's syndromeHatemi, Gülena,b Author Information aDivision of Rheumatology, Department of Internal Medicine, Cerrahpasa Medical Faculty bBehçet's Disease Research Center, Istanbul University-Cerrahpasa Istanbul, Turkey Correspondence to Gülen Hatemi, MD, Professor of Medicine, Division of Rheumatology, Department of Internal Medicine and Behçet's Disease Research Center, Istanbul University-Cerrahpasa, Istanbul, Turkey. Tel: +90 212 414 3000/21793; e-mail: [email protected] Current Opinion in Rheumatology: January 2022 - Volume 34 - Issue 1 - p 39-45 doi: 10.1097/BOR.0000000000000854 Buy Metrics Abstract Purpose of review Treat-to-target (T2T) approach has improved outcomes in chronic diseases. The aim of this review is to discuss the long-term goals and review the evidence for possible targets that would predict the achievement of these goals for developing a T2T strategy for Behçet's syndrome. Recent findings There are no trials comparing a tight control strategy to standard care in Behçet's syndrome but recent studies suggest better outcomes with earlier use of biologic agents compared with sustained conventional treatment. Fluorescein angiography may be a reliable tool for assessing remission in uveitis as fluorescein angiography findings were shown to predict relapses and long-term visual outcome. Good recanalization on Doppler ultrasonography can be a target for venous involvement as this was the only predictor of relapse. Fecal calprotectin levels were associated with small intestinal and colonic ulcers and may be used as a surrogate for remission of gastrointestinal involvement. Summary There are several new treatment modalities that are tried for Behçet's syndrome and ongoing work on outcome measures for reliable disease assessment. In order to ensure the wise and efficient use of treatment modalities, development and implementation of T2T strategies are needed through multidisciplinary and multinational efforts that include patient research partners. Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.